



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 7

Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-005912US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
DK	686	6,972,127	12-06-2005	Schenk	
	679	2005/0255122 A1	11-17-2005	Schenk	
	680	2005/0249727 A1	11-10-2005	Schenk	
	674	6,962,707	11-08-2005	Schenk	
	656	6,946,135	09-20-2005	Schenk	
	693	2005/0191314 A1	09-01-2005	Schenk	
	685	2005/0163788 A1	07-28-2005	Schenk	
	657	6,913,745	07-05-2005	Schenk	
	658	6,905,686	06-14-2005	Schenk	
	659	6,890,535	05-10-2005	Schenk	
	683	2005/0059802 A1	03-17-2005	Schenk et al.	
	684	2005/0059591 A1	03-17-2005	Schenk et al.	
	661	2005/0009150 A1	01-13-2005	Basi et al.	
	673	6,808,712	10-26-2004	Schenk	
	667	6,787,523	09-07-2004	Schenk	
	670	6,787,144	09-07-2004	Schenk	
	668	6,787,143	09-07-2004	Schenk	
	672	6,787,140	09-07-2004	Schenk	
	669	6,787,138	09-07-2004	Schenk	
	671	6,787,129	09-07-2004	Schenk	
	660	2004/0171815 A1	09-02-2004	Schenk et al.	
	642	5,702,906	12-30-1997	Rosenthal	
	643	5,693,762	12-02-1997	Queen et al.	
	644	5,618,920	04-08-1997	Robinson et al.	
	619	5,530,101	06-25-1996	Queen et al.	
	645	5,258,498	11-02-1993	Huston et al.	
	646	4,816,567	03-28-1989	Cabilly et al.	
	647	4,816,397	03-28-1989	Boss et al.	
	691	11/245,524	filed 10-07-2005	Schenk	
	692	11/245,916	filed 10-07-2005	Schenk	

Examiner
SignatureDate
Considered

3/24/06

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 35655-1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 7

Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-005912US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ²	Number ⁴	Kind Code ⁵ (if known)				
DK	633	WO	96/08665	A2	03-21-1996			
	630	WO	95/17085	A1	06-29-1995			
	648	WO	91/09967	A1	07-11-1991			
	632	JP	07-132033	A	05-23-1995			abst. only
	631	JP	62-267297	A	11-19-1987			abst. only

Examiner
SignatureDate
Considered

3/26/06

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

35655-1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 7

Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-005912US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DK	663	ALBERTS et al., eds. <i>Molecular Biology of The Cell, Third Edition</i> , chapter 23, pages 1208-1209 (1994).	
	649	AMIT et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution," <i>Science</i> , 233:747-753 (1986).	
	588	ANDERSON, J. P., "Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells," <i>Neuroscience Letters</i> , 128(1):126-128 (1991).	
	589	ANDERSON, M. W., "Amending the amyloid hypothesis," <i>The Scientist</i> , 18(20):28-29 (2004).	
	677	ANKARCRONA et al., "Biomarkers for apoptosis in Alzheimer's disease," <i>Int. J. Geriatric Psychiatry</i> , 20:101-105 (2005).	
	681	AULD et al., "Alzheimer's disease and the basal forebrain cholinergic system: relations to β -amyloid peptides, cognition, and treatment strategies," <i>Progress in Neurobiol.</i> , 68:209-245 (2002).	
	590	BACSKAI et al., "Non-Fc-mediated mechanisms are involved in clearance of amyloid- β in vivo by immunotherapy," <i>J. Neurosci.</i> , 22(18):7873-7878 (2002).	
	639	Chimicon International, "Mouse Anti-Amyloid Beta Protein Monoclonal Antibody," Catalog # MAB1561	
	591	CHROMY et al., "Self-assembly of A β (1-42) into globular neurotoxins," <i>Biochemistry</i> , 42(44):12749-12760 (2003).	
	592	CITRON et al., "Evidence that the 42- and 40- amino acid forms of amyloid- β protein are generated from the β -amyloid precursor protein by different protease activities," <i>PNAS</i> , 93(23):13170-13175 (1996).	
	593	CITRON, M., "Alzheimer's disease: treatments in discovery and development," <i>Nat. Neurosci.</i> , 5:1055-1057 (2002).	
	687	COX et al., "Adjuvants—a classification and review of their modes of action," <i>Vaccine</i> , 15(3):248-256 (1997).	
	689	DE LUSTIG et al., "Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations," <i>Rev. In Neurosciences</i> , 5:213-225 (1994).	
	594	DEMATTOIS et al., "Brain to plasma amyloid- β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease," <i>Science</i> , 295(5563):2264-2267 (2002).	
✓	595	DODART et al., "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model," <i>Nat. Neurosci.</i> , 5(5):452-457 (2002).	

Examiner
SignatureDate
Considered

3/26/06

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
35655-1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 7

Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-005912US

596	DODEL et al., "Immunotherapy for Alzheimer's disease," <u>Lancet Neurol.</u> , 2(4):215-220 (2003).
597	DOVEY et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <u>J. Neurochem.</u> , 76(1):173-181 (2001).
598	DUFF et al., "Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1," <u>Nature</u> , 383(6602):710-713 (1996).
599	ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo," <u>J. Clin. Invest.</u> , 112(3):440-449 (2003).
600	FINDEIS, M. A., "Approaches to discovery and characterization of inhibitors of amyloid β -peptide polymerization," <u>Biochem. Biophys. Acta</u> , 1502(1):76-84 (2000).
650	FOOTE et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," <u>J. Mol. Biol.</u> , 224:487-499 (1992).
601	FRENKEL et al., "Reduction of β -amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization," <u>Vaccine</u> , 21(11-12):1060-1065 (2003).
602	FRENKEL et al., "Towards Alzheimer's β -amyloid vaccination," <u>Biologicals</u> , 29(3-4):243-247 (2001).
603	GELINAS et al., "Immunotherapy for Alzheimer's disease," <u>PNAS</u> , 101(suppl. 2):14657-14662 (2004).
634	Genbank Accession number AAB48800, "Anti-DNA immunoglobulin light chain IgG [Mus musculus]," 09/14/01.
635	Genbank Accession number CAA46659, "IgE antibody light chain(VJ)," 06/15/93.
636	Genbank Accession number X65775.1, "M.musculus DNA for IgE antibody light chain (VJ)," 06/15/93.
637	Genbank Accession number AAD26773, "Immunoglobulin heavy chain VH3609-JH3 region [Mus musculus]," 04/22/99.
604	GONG et al., "Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss," <u>PNAS</u> , 100(18):10417-10422 (2003).
605	GREENBERG et al., "Alzheimer disease's double-edged vaccine," <u>Nat. Med.</u> , 9(4):389-390 (2003).
694	GUPTA et al., "Adjuvants for human vaccines—current status, problems, and future prospects," <u>Vaccine</u> , 13(14):1263-1275 (1995).

Examiner
SignatureDate
Considered

3/26/06

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 35655-1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/724,575
		Filing Date	November 28, 2000
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-005912US		
Sheet	5	of	7

DK	606	HAASS, C., "New hope for Alzheimer disease vaccine," <i>Nat Med.</i> , 8(11):1195-1196 (2002).	
	664	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , pages 71-82 (1998).	
	607	HOCK et al., "Generation of antibodies specific for β -amyloid by vaccination of patients with Alzheimer disease," <i>Nat. Med.</i> , 8(11):1270-1275 (2002).	
	662	IDA et al., "Analysis of Heterogeneous β A4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay," <i>J. Biol. Chem.</i> , 271(37):22908-22914 (1996).	
	608	IRIZARRY et al., "Alzheimer disease therapeutics," <i>J. Neuropathol. Exp. Neurol.</i> , 60(10):923-928 (2001).	
	609	JANUS et al., "Transgenic mouse models of Alzheimer's Disease," <i>Physiol. Behav.</i> , 73(5):873-886 (2001).	
	640	JUNG et al., "Alzheimer's Beta-amyloid Precursor Protein Is Expressed on the Surface of Immediately Ex Vivo Brain Cells: a Flow Cytometric Study," <i>J. Neurosci. Res.</i> , 46:336-348 (1996).	
	628	KOFLER et al., "Mechanism of Allergic Cross-Reactions--III. cDNA Cloning and Variable-Region Sequence Analysis of Two IgE Antibodies Specific for Trinitrophenyl," <i>Mol. Immunology</i> , 29(2):161-166 (1992).	
	627	KRISHNAN et al., "Correlation Between the Amino Acid Position of Arginine in VH-CDR3 and Specificity for Native DNA Among Autoimmune Antibodies ^{1,2} ," <i>J. Immunol.</i> , 157(6):2430-2439 (1996).	
	695	KUO et al., "Water-soluble A β (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," <i>J. Biol. Chem.</i> , 271(8):4077-4081 (1996).	
	651	LANDOLFI et al., "The Integrity of the Ball-and Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody," <i>J. Immunology</i> , 166(3):1748-1754 (2001).	
	665	LO et al., "High level expression and secretion of Fc-X fusion proteins in mammalian cells," <i>Protein Engineering</i> , 11(6):495-500 (1998).	
	666	MANDEL et al., "Clinical trials in neurological disorders using AAV vectors: promises and challenges," <i>Curr. Opin. Mol. Ther.</i> , 6(5):482-490 (2004).	
	610	MATTSON et al., "Good and bad amyloid antibodies," <i>Science</i> , 301(5641):1845-1849 (2003).	
	611	MCLAURIN et al., "Therapeutically effective antibodies against amyloid- β peptide target amyloid- β residues and 4-10 and inhibit cytotoxicity and fibrillogenesis," <i>Nat Med.</i> , 8(11):1263-1269 (2002).	
	612	MONSONEGO et al., "Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer's disease," <i>J. Clin. Invest.</i> , 112(3):415-422 (2003).	

Examiner Signature		Date Considered	3/26/06
--------------------	--	-----------------	---------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 35655-1





PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 7

Complete If Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-005912US

DK	613	MONSONEGO et al., "Immunotherapeutic approaches to Alzheimer's disease," <i>Science</i> , 302(5646):834-838 (2003).
	652	ORLANDI et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <i>PNAS</i> , 86:3833-3837 (1989).
	614	PAGANETTI et al., "Amyloid precursor protein truncated at any of the γ -secretase sites is not cleaved to β -amyloid," <i>J. Neurosci. Res.</i> , 46(3):283-293 (1996).
	615	PALLITTO et al., "Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity," <i>Biochemistry</i> , 38(12):3570-3578 (1999).
	654	PANKA et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <i>PNAS</i> , 85:3080-3084 (1998).
	682	PARNETTI et al., "Cognitive Enhancement Therapy for Alzheimer's Disease, The Way Forward," <i>Drugs</i> , 53(5):752-768 (1997).
	653	PAUL, W. E., eds., <i>Fundamental Immunology</i> , Third Edition, pages 292-295, Raven Press, New York (1993).
	616	PFEIFER et al., "Cerebral hemorrhage after passive anti-A β immunotherapy," <i>Science</i> , 298(5597):1379 (2002).
	641	RACKE et al., "Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of amyloid β ," <i>J. Neurosci.</i> , 25(3):629-636 (2005).
	638	Research Corporation Technology News, "THP and SangStat Partner to Develop Humanized Polyclonal Antibody Drugs," 11/11/02.
	626	"Researchers Develop Blood Test to Diagnose Alzheimer's- Type Changes in Mice," downloaded from www.businesswire.com on 12/15/04.
	655	RUDIKOFF et al., "Single amino acid substitution altering antigen-binding specificity," <i>PNAS</i> , 79:1979-1983 (1982).
	617	SCHMID, R. E., "Study suggest Alzheimer vaccine fix," from www.msnbc.com/news, pages 1-5 (2002).
	629	SEIDL et al., "Predominant V _H genes expressed in innate antibodies are associated with distinctive antigen-binding sites," <i>PNAS</i> , 96:2262-2267 (1999).
	618	SELKOE, D. J., "Alzheimer's disease is a synaptic failure," <i>Science</i> , 298(5594):789-791 (2002).
✓	622	SERGEANT et al., "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <i>J. Neurochem.</i> , 85(6):1581-1591 (2003).

Examiner
SignatureDate
Considered


3/26/06

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

35655-1



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 7

Complete If Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.
Attorney Docket Number	15270J-005912US

DK	620	SOLOMON, B., "Generation and brain delivery of anti-aggregating antibodies against β -amyloid plaques using phage display technology," <i>J. Neural Transm. Suppl.</i> , 62:321-325 (2002).	
	621	SOLOMON, B., "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease," <i>DNA and Cell Biology</i> , 20(11):697-703 (2001).	
	678	SOUDER et al., "Overview of Alzheimer's disease," <i>Nurs. Clin. N. Am.</i> , 39:545-559 (2004).	
	690	VICKERS, J. C., "A Vaccine Against Alzheimer's Disease," <i>Drugs Aging</i> , 19(7):487-494 (2002).	
	623	WALSH et al., "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo," <i>Nature</i> , 416(6880):535-539 (2002).	
	624	WASHINGTON UNIVERSITY IN ST. LOUIS SCHOOL OF MEDICINE, "Study gives Clues to Working of Anti-Alzheimer Antibody," downloaded from www.medicine.wustl.edu/~wumpa/news on 12/15/04.	
	676	<i>Webster's New World Dictionary</i> , page 1387, therapeutic (1988).	
	688	<i>Webster's New World Dictionary of American English</i> , Third College Edition, page 1078 (1988).	
✓	625	WHITE et al., "Immunotherapy as a therapeutic treatment for neurodegenerative disorders," <i>J. Neurochem.</i> , 87(4):801-808 (2003).	

Examiner
Signature

Date
Considered

3/26/06

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
35655-1